Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no generic or cheaper alternative version of Wegovy currently licensed in the UK. Wegovy (semaglutide 2.4mg and above) is a branded, prescription-only medicine made by Novo Nordisk, and no biosimilar has received MHRA approval for weight management yet. Private monthly prices in the UK typically range from around £149 to £375 depending on dose and provider, figures that shifted notably when Eli Lilly raised its own list prices in September 2025. That context matters before you search for a cheaper route: a lower price on a prescription medicine is not automatically a better deal, and the wrong source can be genuinely dangerous. What you are really asking is whether a clinically safe, affordable, regulated path exists — and that is a question worth answering properly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
NICE recommended semaglutide (Wegovy) for weight management in March 2023, but its guidance under NICE technology appraisal TA875 restricts NHS access to specialist weight management services, for a maximum of two years, and only for adults with a BMI of 35 or above alongside at least one weight-related condition. That narrow NHS pathway, and the long waiting lists that come with it, is why most people paying privately are doing so. And private pricing reflects the medicine's actual licensed status: semaglutide is a biological medicine manufactured under tightly controlled conditions, not a small-molecule drug that a generic company can easily replicate. The MHRA has not yet approved a biosimilar semaglutide for weight management. That regulatory reality is the single biggest reason no cheaper version of Wegovy exists right now.
The STEP 1 trial, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. Clinical results at that scale are built on years of development, regulatory review and pharmacovigilance, costs that feed directly into the list price. Understanding that is useful, because it reframes the question. The right question is not "how do I get Wegovy cheaper?" but "how do I access it safely, at a price that is clear and complete?" If you are wondering whether Wegovy is going to get cheaper, the regulatory pipeline and market dynamics suggest the answer is more complicated than it first appears.
If you want to understand whether the price gap between providers is likely to close over time, our look at whether Wegovy will get cheaper in the UK covers what the regulatory pipeline and market dynamics suggest.
Scroll through enough provider listings and you will find prices that look significantly lower than others. Before assuming they represent a genuine saving, it is worth knowing what those figures frequently exclude. Many advertised prices do not include a consultation fee, charged separately, sometimes regardless of whether you are approved. Some do not include the prescription itself. Delivery charges are common, and expedited or tracked delivery can cost extra on top. Aftercare (the clinical check-in that should happen before your dose changes or your next supply is issued) is omitted entirely by some providers, passed to a generic chatbot, or charged as an add-on.
A price comparison only means something when every column contains the same items. Consultation, prescription, the medicine, tracked delivery and ongoing clinical support are all part of safe treatment. Strip any of those out and you are not comparing prices, you are comparing what is and is not included. That matters particularly with a titrated medicine: semaglutide starts at 0.25mg and works up through several dose steps, each of which should be reviewed clinically before the next supply goes out. If that review is not happening, the saving is coming from somewhere the clinical guidance says it should not.
For a detailed breakdown of what drives Wegovy pricing across the market, the Wegovy cost guide sets out the full picture without competitor names.
A named prescriber (not software) reads every consultation at nume the same day. That clinical review covers your full health picture: weight verified on video, photo ID confirmed, GP notification in line with GPhC guidance, and a careful look at any medicines you already take. Prescriptions are written only where the clinical case supports it. All of that is included in one price, alongside free next-working-day DPD delivery and seven-day aftercare.
We are not the cheapest option available. That is a deliberate choice, not an oversight. Cutting the consultation, skipping the aftercare, or sourcing from outside the licensed UK supply chain are the routes through which prices fall below a certain floor, and none of those routes is one we are willing to take. Current treatment pricing is shown on our treatment page, and there are no hidden charges added at any point. If you want to understand what is included in more detail before you start, the FAQs cover the most common questions our prescribers hear.
If you are specifically looking at how the starting dose is priced, the 0.25mg cost breakdown explains how the initial phase works.
The MHRA has issued repeated public warnings about fake weight-loss pens sold online and via social media. In one enforcement operation in late 2025, approximately 20 million doses of illegally traded weight-loss medicines (worth around £45 million) were seized, and a site producing counterfeit tirzepatide pens was raided in Northampton. Fake pens have in some cases contained insulin rather than semaglutide, with serious consequences for the people who used them. You can report a suspect seller or a suspected counterfeit product at the MHRA's Yellow Card scheme.
The red flags are consistent: sellers offering these medicines without a prescription, social media accounts with no pharmacy registration, prices far below the realistic market range, and discount codes. If a listing offers a voucher code for a prescription-only medicine, that is not a sign of good value, it is a compliance warning. Legitimate pharmacies, dispensing licensed medicines through a verified supply chain, do not discount the medicine itself.
The question to ask is not whether a provider is cheapest but whether it is registered. Any UK online pharmacy can be checked on the GPhC register at pharmacyregulation.org; nume's premises registration number is 9012878. That verification takes thirty seconds and tells you more than a price comparison ever can. For a fuller look at how to access Wegovy through a safe, regulated route, this guide on accessing Wegovy cost-effectively walks through the practical steps. And if a Wegovy consultation sounds like the right next move, order by 12pm on a working day and, once approved, your treatment goes out the same afternoon.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.